These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38095822)

  • 1. Lecanemab: More Questions Than Answers!
    Kaur U; Reddy J; Tiwari A; Chakrabarti S; Chakrabarti SS
    Clin Drug Investig; 2024 Jan; 44(1):1-10. PubMed ID: 38095822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
    Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
    Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.
    Kepp KP; Sensi SL; Johnsen KB; Barrio JR; Høilund-Carlsen PF; Neve RL; Alavi A; Herrup K; Perry G; Robakis NK; Vissel B; Espay AJ
    J Alzheimers Dis; 2023; 94(2):497-507. PubMed ID: 37334596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.
    Hossain MF; Husna AU; Kharel M
    Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Abdelazim K; Allam AA; Afifi B; Abdulazeem H; Elbehiry AI
    Neurol Sci; 2024 Aug; 45(8):3583-3597. PubMed ID: 38565747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
    McDade E; Cummings JL; Dhadda S; Swanson CJ; Reyderman L; Kanekiyo M; Koyama A; Irizarry M; Kramer LD; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):191. PubMed ID: 36544184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Ebell MH; Barry HC; Baduni K; Grasso G
    Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lecanemab: Appropriate Use Recommendations.
    Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
    J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
    Vitek GE; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
    Beveridge J; Kaniecki E; Naidu A; Silverglate BD; Grossberg G
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):35-43. PubMed ID: 38193477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lecanemab Questions.
    Nadeau SE
    Neurology; 2024 Apr; 102(7):e209320. PubMed ID: 38484213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More failure with solanezumab - this time in preclinical Alzheimer's disease.
    Doggrell SA
    Expert Opin Biol Ther; 2024 Mar; 24(3):119-123. PubMed ID: 38414336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approves Alzheimer's drug lecanemab amid safety concerns.
    Reardon S
    Nature; 2023 Jan; 613(7943):227-228. PubMed ID: 36627422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.